PURPOSE: The epidemiology of colorectal carcinoma is well known to differ among countries but the molecular characteristics are usually assumed to be similar. International differences in molecular pathology have not been studied extensively but have implications for the management of patients in different countries and of immigrant patients. EXPERIMENTAL DESIGN: We evaluated the CpG island methylator phenotype pathway characterized by concordant methylation of gene promoters that often silences transcription of the genes, the microsatellite instability pathway, and K-ras and p53 gene status in 247 colorectal carcinomas from the three selected Middle Eastern countries of Egypt, Jordan, and Turkey. RESULTS: Colorectal carcinoma from Egypt had the lowest frequencies of methylation. In multinomial logistic regression analysis, Jordanian colorectal carcinoma more frequently had methylation involving the p16 tumor suppressor gene (odds ratio, 3.5; 95% confidence interval, 1.2-10.6; P = 0.023) and MINT31 locus (odds ratio, 2.3; 95% confidence interval, 1.0-5.1; P = 0.041). The K-ras proto-oncogene was more frequently mutated in colorectal carcinoma from Turkey (odds ratio, 2.9; 95% confidence interval, 1.2-6.7; P = 0.016), but p53 overexpression was more common in both Jordanian and Turkish colorectal carcinoma than in Egyptian cases (odds ratio, 2.5; 95% confidence interval, 1.2-5.5; P = 0.019; and odds ratio, 3.6; 95% confidence interval, 1.8-7.1; P = 0.0003, respectively). The findings in Turkish colorectal carcinoma were most similar to those reported for Western cases. CONCLUSIONS: Colorectal carcinoma from Middle Eastern countries have differing gene methylation patterns and mutation frequencies that indicate dissimilar molecular pathogenesis, probably reflecting different environmental exposures. These molecular differences could affect prevention strategies, therapeutic efficacy, and transferability of clinical trial results.
PURPOSE: The epidemiology of colorectal carcinoma is well known to differ among countries but the molecular characteristics are usually assumed to be similar. International differences in molecular pathology have not been studied extensively but have implications for the management of patients in different countries and of immigrant patients. EXPERIMENTAL DESIGN: We evaluated the CpG island methylator phenotype pathway characterized by concordant methylation of gene promoters that often silences transcription of the genes, the microsatellite instability pathway, and K-ras and p53 gene status in 247 colorectal carcinomas from the three selected Middle Eastern countries of Egypt, Jordan, and Turkey. RESULTS:Colorectal carcinoma from Egypt had the lowest frequencies of methylation. In multinomial logistic regression analysis, Jordanian colorectal carcinoma more frequently had methylation involving the p16tumor suppressor gene (odds ratio, 3.5; 95% confidence interval, 1.2-10.6; P = 0.023) and MINT31 locus (odds ratio, 2.3; 95% confidence interval, 1.0-5.1; P = 0.041). The K-ras proto-oncogene was more frequently mutated in colorectal carcinoma from Turkey (odds ratio, 2.9; 95% confidence interval, 1.2-6.7; P = 0.016), but p53 overexpression was more common in both Jordanian and Turkish colorectal carcinoma than in Egyptian cases (odds ratio, 2.5; 95% confidence interval, 1.2-5.5; P = 0.019; and odds ratio, 3.6; 95% confidence interval, 1.8-7.1; P = 0.0003, respectively). The findings in Turkish colorectal carcinoma were most similar to those reported for Western cases. CONCLUSIONS:Colorectal carcinoma from Middle Eastern countries have differing gene methylation patterns and mutation frequencies that indicate dissimilar molecular pathogenesis, probably reflecting different environmental exposures. These molecular differences could affect prevention strategies, therapeutic efficacy, and transferability of clinical trial results.
Authors: Joo Mi Yi; Mashaal Dhir; Leander Van Neste; Stephanie R Downing; Jana Jeschke; Sabine C Glöckner; Marilia de Freitas Calmon; Craig M Hooker; Juan M Funes; Chris Boshoff; Kim M Smits; Manon van Engeland; Matty P Weijenberg; Christine A Iacobuzio-Donahue; James G Herman; Kornel E Schuebel; Stephen B Baylin; Nita Ahuja Journal: Clin Cancer Res Date: 2011-01-28 Impact factor: 12.531
Authors: Humaid O Al-Shamsi; Jeremy Jones; Yazan Fahmawi; Ibrahim Dahbour; Aziz Tabash; Reham Abdel-Wahab; Ahmed O S Abousamra; Kenna R Shaw; Lianchun Xiao; Manal M Hassan; Benjamin R Kipp; Scott Kopetz; Amr S Soliman; Robert R McWilliams; Robert A Wolff Journal: J Gastrointest Oncol Date: 2016-12
Authors: Narayan Shivapurkar; Mark E Sherman; Victor Stastny; Chinyere Echebiri; Janet S Rader; Ritu Nayar; Thomas A Bonfiglio; Adi F Gazdar; Sophia S Wang Journal: Gynecol Oncol Date: 2007-09-25 Impact factor: 5.482
Authors: Darlene Veruttipong; Amr S Soliman; Samuel F Gilbert; Taylor S Blachley; Ahmed Hablas; Mohamed Ramadan; Laura S Rozek; Ibrahim A Seifeldin Journal: World J Gastroenterol Date: 2012-08-14 Impact factor: 5.742
Authors: Cristina E Aguilar; Amr S Soliman; Daniel S McConnell; Abdel-Rahman Zekri; Mousumi Banerjee; Ayman Omar; Mohamed Sharawy; Sherif Omar; Ahmed Raouf; Maryfran R Sowers Journal: J Gastroenterol Hepatol Date: 2007-05-24 Impact factor: 4.029